Last reviewed · How we verify
NCT06318286: PENINSULA
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Phase 2 trial testing Lenvatinib in Malignant Pleural Mesothelioma in 25 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Hyogo Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 13 March 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Lenvatinib (LENVATINIB) — full drug profile →
- Pemetrexed — full drug profile →
- Cisplatin/Carboplatin
- Pembrolizumab (pembrolizumab) — full drug profile →
Conditions studied
- Malignant Pleural Mesothelioma — all drugs for Malignant Pleural Mesothelioma →
Sponsor
Hyogo Medical University
Who can join
18 and older, any sex, with Malignant Pleural Mesothelioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06318286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lenvatinib
Trials testing the same drug.
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
- NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting
Other recruiting trials for Malignant Pleural Mesothelioma
Currently open trials in the same condition.
- NCT05655078 — Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma · NA · recruiting
- NCT04400539 — The IMmunotherapy Pleural 5-ALA PDT · Phase 2 · recruiting
Other Hyogo Medical University trials
Trials by the same sponsor.
- NCT07347665 — Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle C · NA · recruiting
- NCT03702413 — Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic Core · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06318286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hyogo Medical University
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06318286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing